Mr. Lieber was a founding partner at R&D Capital, a private investment group. Until 2011, Mr. Lieber served as CEO of Sphera Funds Management, Israel’s largest and most successful hedge fund management firm. Mr. Lieber holds a B.Sc. in Economics from Bar Ilan University and is a graduate of Harvard Business School’s Advanced Management Program (AMP).
Dr. Gil RonenFounder & CEO
Prior to establishing NRGene, Dr. Ronen was extensively involved in plant genomics at Compugen (Nasdaq: CGEN) and the AgBio discovery company Evogene (Nyse: EVGN). His last held positions at Evogene were as Chief Scientist and VP of Intellectual Property. Dr. Ronen holds a B.Sc. in Agronomy and a Ph.D. in Plant Genetics, both from The Hebrew University of Jerusalem.
Guy KolSVP Product & Strategic Alliances
Mr. Kol has 15 years of experience in industrial computational biology. From 2005 to 2007, he served as the Bioinformatics team leader of Evogene, where he collaborated with Dr. Ronen. Mr. Kol holds a B.Sc. in Computer Science, Biology and Mathematics from The Hebrew University of Jerusalem, a M.Sc. in Human Genetics from Tel Aviv University and an MBA from Babson College in Wellesley, MA.
Dr. Omer BaradVP R&D
Dr. Barad has extensive experience in developing mathematical models and algorithms for the analysis of biological data. Dr. Barad joined NRGene in 2011, he lead the algorithmic team and served as the company CTO before assuming his latest role. From 2004 to 2007, he served as a senior scientist at Rosetta Genomics. Dr. Barad holds a B.Sc. in Physics and Computer Science from Tel-Aviv University, an MSc in Physics and a PhD in Life Science both from The Weizmann Institute.
Eli Ben-PoratVP Sales & Business Development
Mr. Ben-Porat brings more than 15 years of experience as senior Business Development and Strategic Consultant. From 2006 to 2011, he served as Director of Business Development at Zeraim Gedera, a leading seed company that was acquired by Syngenta. Mr. Ben-Porat holds an MBA in Finance from Tel Aviv University and a BA in Economics, Business Management Major, from Ben Gurion University.
Ms. Kreiner brings more than 10 years of experience in various finance management and operations positions. Ms. Kreiner’s previous positions, which include CFO of Therapix biosciences (Tase: TRPX) and Director of Finance at Evogene through their IPO, highlight her .success in the biotech sector Ms. Kreiner holds a BA in Accounting and Economics and an MBA in Finance and Marketing from .Tel Aviv University.
Dr. Kobi BaruchVP Production & Professional Services
Dr. Baruch joined NRGene in 2011 and served in a number of key roles in its R&D team before assuming his latest role. He has extensive experience in computational and molecular biology and holds a B.Sc. in computer science and biology from Bar Ilan University, an M.Sc. in genomics and bioinformatics and a Ph.D. in molecular genetics and microbiology from the Hebrew University, as well as an MBA from the Ono Academic College.
Dr. Itai KelaDirector of BD, Clinical Genomics
Before joining NRGene, Dr. Kela held a variety of executive positions in Cell Gene Actor (CGA), Protalix (NASDAQ:PLX) and Stem Cell Medicine. Dr. Kela holds a PhD in cancer genomics from the Weizmann Institute of Science and specialized in Cancer Genomics at the Stanford University and the Stanford Genome Center. Dr. Kela won The Center of System Biology Award from the Weizmann Institute of Science.